Previous 10 | Next 10 |
home / stock / bpmuf / bpmuf news
Basilea Pharmaceutica AG (BPMUF) Q2 2020 Results Conference Call August 11, 2020 10:00 AM ET Company Participants David Veitch - Chief Executive Officer Adesh Kaul - Chief Financial Officer Dr. Marc Engelhardt - Chief Medical Officer Conference Call Participants Louise Chen...
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with their 2019 Q4 earnings Read more ...
Basilea Pharmaceutica Ltd. (BPMUF) Q4 2019 Earnings Conference Call February 18, 2020 10:00 AM ET Company Participants David Veitch – Chief Executive Officer Adesh Kaul – Chief Financial Officer Marc Engelhardt – Chief Medical Officer Conference Call Parti...
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with this Read more ...
Basilea Pharmaceutica AG (BPMUF) Q2 2019 Results Earnings Conference Call August 20, 2019, 10:00 AM ET Company Participants David Veitch - CEO Adesh Kaul - CFO Marc Engelhardt - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Bob Pooler - valuation...
Basilea Pharmaceutica AG ( OTC:BPMUF ): 1H GAAP EPS of -CHF1.44. More news on: Basilea Pharmaceutica AG, Earnings news and commentary, Healthcare stocks news, Read more ...
Basilea Pharmaceutica Ltd. (BPMUF) Q4 2018 Results Conference Call February 15, 2019 10:00 AM ET Company Participants David Veitch - CEO Adesh Kaul - Chief Corporate Development Officer Dr. Marc Engelhardt - Chief Medical Officer Donato Spota - CFO Conference Call Participa...
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with their 2018 Q4 earnings Read more ...
Recently, the ArQule’s lead candidate, derazantinib, showed positive preliminary action from a Phase 2 liver cancer study. In addition, ArQule reported that partner Basilea Pharmaceutica (OTC: BPMUF ) will team up with Roche (OTCQX: RHHBY ) to assess the combination of derazantinib,...
ArQule (NASDAQ: ARQL ) announces that licensee Basilea Pharmaceutica ( OTC:BPMUF ) will collaborate with Roche ( OTCQX:RHHBY ) to evaluate the combination of BAL087 (derazantinib) (formerly ARQ087), a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, and Tecentriq (atezolizuma...
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
China Yuchai International Limited (CYD) is expected to report for Q1 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Derwent London Plc (DWVYF) is expected to report for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Basilea Pharmaceutic...
GreenTree Hospitality Group Ltd. American depositary shares each representing one Class A (GHG) is expected to report for Q1 2024 Air T Inc. (AIRT) is expected to report for Q4 2024 Alimentation-Couche Tard Inc. - Class A (Multiple Voting) (ANCTF) is expected to report for Q4 2024 Man...
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement w...